Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AMDL, a US-based pharmaceutical company with operations in China, has signed Precision Diagnostic Laboratory, a provider of diagnostic services, as its first customer to offer the AMDL DR-70 in vitro cancer test to patients and doctors in the US.
Subscribe to our email newsletter
With this agreement, Precision Diagnostic Laboratory (PDL) is the first diagnostic laboratory in the US to offer the AMDL DR-70 (FDP) in vitro cancer test to doctors and their patients. To drive product awareness and education, AMDL and PDL will jointly train physicians and market the product to physicians and their patients in the US.
AMDL’s DR-70 (FDP) is a FDA-approved cancer test that can be easily and inexpensively added to the pre-existing line of diagnostics routinely performed by physicians and clinical laboratories through out the US.
AMDL received clearance from the US FDA to market DR-70 for the monitoring of colorectal cancer on July 3, 2008. The product has also been cleared in other international markets including Canada for the detection of lung cancer, Korea and Taiwan as a general cancer screen, and has the CE mark from the EU for product sales in Europe as a general cancer screen.
Doug MacLellan, executive chairman and CEO of AMDL, said: “This is a significant and highly-anticipated milestone in the commercialization and distribution for our DR-70 cancer test. We have extremely aggressive business and financial targets for this product and are very pleased to initiate sales with a highly-respected diagnostic lab like PDL for this potentially life-saving cancer test.”